About Censa Pharmaceuticals
Censa Pharmaceuticals is a company based in Cambridge (United States) founded in 2015 was acquired by PTC Therapeutics in May 2020. Censa Pharmaceuticals has raised $3.01 million across 2 funding rounds from investors including PTC Therapeutics. The company has 2 employees as of December 31, 2022. Censa Pharmaceuticals operates in a competitive market with competitors including Harmony Biosciences, QurAlis, Evox Therapeutics, Passage Bio and Longboard Pharmaceutical, among others.
- Headquarter Cambridge, United States
- Employees 2 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Censa Pharmaceuticals Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.01 M (USD)
in 2 rounds
-
Latest Funding Round
$1.5 M (USD), Seed
Nov 21, 2017
- Investors
-
Employee Count
2
as on Dec 31, 2022
-
Acquired by
PTC Therapeutics
(May 06, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Censa Pharmaceuticals
Censa Pharmaceuticals has successfully raised a total of $3.01M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.5 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Censa Pharmaceuticals
Censa Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PTC Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Small molecule drugs for rare diseases are developed.
|
Locked | Locked | Locked |
Investor details for Censa Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Censa Pharmaceuticals
Investment portfolio details for Censa Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Censa Pharmaceuticals
Detailed financials for Censa Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Censa Pharmaceuticals Comparisons
Peer comparison for Censa Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Censa Pharmaceuticals
Censa Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harmony Biosciences, QurAlis, Evox Therapeutics, Passage Bio and Longboard Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
|
| Locked | Locked | Locked |
Drugs and CSF devices are developed for ALS treatment.
|
|
| Locked | Locked | Locked |
Exosome-based gene therapies for neurological diseases are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for CNS rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for rare neurological diseases are developed.
|
|
| Locked | Locked | Locked |
CNS therapeutics are developed via regenerative medicine for disorders.
|
Detailed competitors of Censa Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Censa Pharmaceuticals
Complete news archive for Censa Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Censa Pharmaceuticals
Censa Pharmaceuticals was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Censa Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Censa Pharmaceuticals is a funded company, having raised a total of $3.01M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Censa Pharmaceuticals is 2.
Founded in 2015 in Cambridge, United States, Censa Pharmaceuticals operates in the pharmaceutical sector at the preclinical stage. Drugs are developed for rare central nervous system disorders, emphasizing issues in neurotransmitter degradation and synthesis. The lead candidate, CNSA-001, advances through discovery for Tetrahydrobiopterin deficiency, which involves shortages of BH4 and altered phenylalanine levels. FDA and EMA approvals are targeted within four years, while parallel programs address broader CNS conditions.
Censa Pharmaceuticals's top competitors include Harmony Biosciences, QurAlis and MindMed.
Censa Pharmaceuticals has 1 investor. Key investors include PTC Therapeutics.